Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
- PMID: 19448591
- DOI: 10.1038/modpathol.2009.78
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
Abstract
The HER2 gene is an important prognostic and therapeutic marker in newly diagnosed breast cancer. Currently, HER2 status is most frequently determined by immunohistochemical detection of HER2 protein expression on the cellular membrane surface or by fluorescence in situ hybridization analysis of HER2 gene copy number in fixed tissue using locus-specific probes for the HER2 gene and chromosome 17 centromere. However, these methods are problematic because of issues with intra- and inter-laboratory reproducibility and preanalytic variables, such as fixation time. In addition, the commonly used HER2/chromosome 17 ratio presumes that chromosome 17 polysomy is present when the centromere is amplified, even though analysis of the rest of the chromosome is not included in the assay. In this study, 97 frozen samples of invasive lobular and invasive ductal carcinoma, with known immunohistochemistry and fluorescence in situ hybridization results for HER2, were analyzed by comparative genomic hybridization to a commercially available bacterial artificial chromosome whole-genome array containing 99 probes targeted to chromosome 17 and the HER2/TOP2 amplicon. Results were 97% concordant for HER2 status, meeting the College of American Pathologists/American Society of Clinical Oncology's validation requirements for HER2 testing. Surprisingly, not a single case of complete polysomy 17 was detected even though multiple breast cancer cases showed clear polysomies of other chromosomes. We conclude that array comparative genomic hybridization is an accurate and objective DNA-based alternative for clinical evaluation of HER2 gene copy number, and that polysomy 17 is a rare event in breast cancer.
Similar articles
-
Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.BMC Cancer. 2010 Jul 28;10:396. doi: 10.1186/1471-2407-10-396. BMC Cancer. 2010. PMID: 20667129 Free PMC article.
-
Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.Int J Clin Exp Pathol. 2013 Dec 15;7(1):163-73. eCollection 2014. Int J Clin Exp Pathol. 2013. PMID: 24427336 Free PMC article.
-
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.J Pathol. 2009 Sep;219(1):16-24. doi: 10.1002/path.2574. J Pathol. 2009. PMID: 19670217
-
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol. 2014 Jan;27(1):4-18. doi: 10.1038/modpathol.2013.103. Epub 2013 Jun 28. Mod Pathol. 2014. PMID: 23807776 Review.
-
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Ann Pathol. 2011. PMID: 22172120 Review. French.
Cited by
-
Classification of HER2-negative breast cancers by ERBB2 copy number alteration status reveals molecular differences associated with chromosome 17 gene aberrations.Ther Adv Med Oncol. 2023 Oct 31;15:17588359231206259. doi: 10.1177/17588359231206259. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37920257 Free PMC article.
-
The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.Histopathology. 2022 Oct;81(4):511-519. doi: 10.1111/his.14728. Epub 2022 Aug 8. Histopathology. 2022. PMID: 35879836 Free PMC article.
-
Updates on breast biomarkers.Virchows Arch. 2022 Jan;480(1):163-176. doi: 10.1007/s00428-022-03267-x. Epub 2022 Jan 14. Virchows Arch. 2022. PMID: 35029776 Review.
-
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline.Diagn Pathol. 2022 Jan 7;17(1):5. doi: 10.1186/s13000-021-01187-z. Diagn Pathol. 2022. PMID: 34996485 Free PMC article.
-
Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches.Int J Mol Sci. 2021 Apr 29;22(9):4732. doi: 10.3390/ijms22094732. Int J Mol Sci. 2021. PMID: 33946969 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous